LANCL1 Inhibitors
LANCL1 inhibitors are a category of chemical compounds designed to target and modulate the activity of LANCL1, which stands for LanC-like protein 1. LANCL1 is a protein that belongs to the LanC-like protein family, and while its precise functions are still under investigation, it has been implicated in various cellular processes, including potential roles in immune response regulation and metabolism. Inhibitors of LANCL1 are developed to interact with this specific protein, potentially influencing its binding to ligands, interactions with other cellular components, or its participation in signaling pathways where LANCL1 may be involved.
Structurally, LANCL1 inhibitors are carefully designed to engage specific regions or binding sites on the LANCL1 protein. This interaction may disrupt the normal functioning of LANCL1, potentially affecting its ability to modulate cellular processes or its involvement in cellular signaling cascades.
The mechanisms by which LANCL1 inhibitors exert their effects can vary, but their primary objective is to serve as valuable tools for researchers studying the roles of LANCL1 in various cellular contexts. Investigating the biochemical and functional aspects of LANCL1 and its modulation by inhibitors can contribute to a deeper understanding of immune regulation, metabolic processes, and the broader field of molecular and cellular biology. Ultimately, such research can offer insights into the intricate molecular mechanisms that govern fundamental cellular functions and their potential regulation by LANCL1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
An AMPK activator, it might influence LANCL1 indirectly through AMPK-mediated pathways. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
As a PPARγ agonist, it could potentially influence pathways where LANCL1 is active. | ||||||
T0070907 | 313516-66-4 | sc-203287 | 5 mg | $141.00 | 1 | |
This PPARγ antagonist might have indirect effects on LANCL1 through PPARγ-related pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
By inhibiting mTOR, rapamycin might affect pathways that can indirectly modulate LANCL1. | ||||||
WZ8040 | 1214265-57-2 | sc-364656 sc-364656A | 5 mg 10 mg | $255.00 $480.00 | ||
Inhibits NUAK1/2, which are related to AMPK signaling. Might have an indirect influence on LANCL1. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
By inhibiting calcineurin and modulating NFAT signaling, it might indirectly affect LANCL1 pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
As a PI3K inhibitor, LY294002 could influence pathways that might be related to LANCL1's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of the MAPK pathway, which might intersect with LANCL1-related pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that might indirectly affect LANCL1 through the MAPK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor which might influence pathways potentially linked with LANCL1. | ||||||